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Objective/purpose
CD103 (Alpha-E Beta-7 integrin) is expressed on various
cell types involved in the development of asthma,
including dendritic cells (DCs) and CD4 and CD8 T
regulatory cells. This integrin binds E-cadherin on
epithelial cells and plays a role in regulating the migra-
tion and proliferation of cells. Also, CD103
+ dendritic
cells have been reported to direct the development of
naïve T cells into T regulatory cells. However, little is
known about the exact role of CD103 in the develop-
ment of asthma. The objective of this project is to inves-
tigate the role of this integrin in asthma pathogenesis, in
the hope of finding new molecular targets for the treat-
ment of asthma.
Methods
Asthma was induced in wild type C57Bl/6 and Cd103
-/-
mice. Briefly, mice were sensitized to Ovalbumin (OVA)
through two 100 μl intraperitoneal injections of 0.02%
OVA coupled to aluminium hydroxide on days 1 and 8.
Mice were then challenged intranasally with 50 μlo f2 %
OVA on days 22, 23, 24, 26 and 28, and sacrificed on
day 29. The assessment of airway inflammation was per-
formed by analysis of the broncho-alveolar lavage (BAL)
content as well as the hematopoietic content of collage-
nase-digested lungs, where the numbers of lymphocytes,
macrophages, neutrophils, eosinophils, myeloid dendritic
cells, lymphoid dendritic cells, plasmacytoid dendritic
cells and T regulatory cells were determined. Cytokine
production in recall to OVA was tested in both lung
hematopoietic cells and the draining lymph nodes.
Finally, airway hyperresponsiveness was tested via a
methacholine challenge, using a flexiVent apparatus.
Findings
The analysis of airway inflammation revealed that lack
of CD103 expression leads to worse asthma compared
to wild type mice, as characterized by an increase in
total BAL cells, in the percentage and total numbers of
eosinophils in the BAL, in cytokine production in recall
to OVA and by an increase in airway resistance in
response to methacholine. CD103 expression did not
seem to affect the accumulation of DCs or T regulatory
cells in the lung tissue at baseline and in response to
OVA. However, lack of CD103 leads to an expansion of
the myeloid dendritic cell population in the lung at
baseline, which could account for the exacerbated dis-
ease observed in these mice.
Deliverables and relevance
In light of these results, we believe that a further under-
standing of CD103 function in the lung could lead to an
interesting new molecular pharmacological target. Also,
as this molecule is expressed specifically on dendritic
cells and T regulatory cells, this research could lead to
new ways of intervening in the process by which these
cells drive the asthmatic response rather than a normal,
non-allergic response.
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